429 related articles for article (PubMed ID: 11705489)
1. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
van Oosterom AT; Judson I; Verweij J; Stroobants S; Donato di Paola E; Dimitrijevic S; Martens M; Webb A; Sciot R; Van Glabbeke M; Silberman S; Nielsen OS;
Lancet; 2001 Oct; 358(9291):1421-3. PubMed ID: 11705489
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.
Jager PL; Gietema JA; van der Graaf WT
Nucl Med Commun; 2004 May; 25(5):433-8. PubMed ID: 15100500
[TBL] [Abstract][Full Text] [Related]
4. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.
van Oosterom AT; Judson IR; Verweij J; Stroobants S; Dumez H; Donato di Paola E; Sciot R; Van Glabbeke M; Dimitrijevic S; Nielsen OS;
Eur J Cancer; 2002 Sep; 38 Suppl 5():S83-7. PubMed ID: 12528778
[TBL] [Abstract][Full Text] [Related]
5. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
Dagher R; Cohen M; Williams G; Rothmann M; Gobburu J; Robbie G; Rahman A; Chen G; Staten A; Griebel D; Pazdur R
Clin Cancer Res; 2002 Oct; 8(10):3034-8. PubMed ID: 12374669
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
[TBL] [Abstract][Full Text] [Related]
7. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).
Stroobants S; Goeminne J; Seegers M; Dimitrijevic S; Dupont P; Nuyts J; Martens M; van den Borne B; Cole P; Sciot R; Dumez H; Silberman S; Mortelmans L; van Oosterom A
Eur J Cancer; 2003 Sep; 39(14):2012-20. PubMed ID: 12957455
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of imatinib mesylate (STI571) on gastrointestinal stromal tumors in Japanese patients.
Sawaki A; Yamao K; Nakamura T; Suzuki T; Okubo K; Hara K; Kawai H; Yamamura Y; Ito S; Mochiduki Y; Ohno R
J Gastroenterol; 2004; 39(4):329-33. PubMed ID: 15168243
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours.
Joensuu H; Dimitrijevic S
Ann Med; 2001 Oct; 33(7):451-5. PubMed ID: 11680792
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
Verweij J; van Oosterom A; Blay JY; Judson I; Rodenhuis S; van der Graaf W; Radford J; Le Cesne A; Hogendoorn PC; di Paola ED; Brown M; Nielsen OS
Eur J Cancer; 2003 Sep; 39(14):2006-11. PubMed ID: 12957454
[TBL] [Abstract][Full Text] [Related]
11. [Effect of imatinib treatment of gastrointestinal stromal tumors].
Eckhardt S; Pápai Z; Bodoky G; Horti J; Tamás K; Nagy T; Orosz Z; Sápi Z; Gödény M; Jakab K; Esik O; Trón L; Besznyák I
Orv Hetil; 2003 Nov; 144(45):2207-12. PubMed ID: 14686005
[TBL] [Abstract][Full Text] [Related]
12. Imatinib for the treatment of patients with unresectable or metastatic malignant KIT-positive gastrointestinal stromal tumours: an open-label Belgian trial.
Prenen H; Dumez H; Stefan C; Hoeben A; Wouters C; Van Lierde MA; Sciot R; van Oosterom AT; Peeters M; Polus M; Duck L; Gil T; Schöffski P
Acta Gastroenterol Belg; 2006; 69(4):367-71. PubMed ID: 17343077
[TBL] [Abstract][Full Text] [Related]
13. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal stromal tumours.
Connolly EM; Gaffney E; Reynolds JV
Br J Surg; 2003 Oct; 90(10):1178-86. PubMed ID: 14515284
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
Demetri GD; von Mehren M; Blanke CD; Van den Abbeele AD; Eisenberg B; Roberts PJ; Heinrich MC; Tuveson DA; Singer S; Janicek M; Fletcher JA; Silverman SG; Silberman SL; Capdeville R; Kiese B; Peng B; Dimitrijevic S; Druker BJ; Corless C; Fletcher CD; Joensuu H
N Engl J Med; 2002 Aug; 347(7):472-80. PubMed ID: 12181401
[TBL] [Abstract][Full Text] [Related]
16. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?
Scaife CL; Hunt KK; Patel SR; Benjamin RS; Burgess MA; Chen LL; Trent J; Raymond AK; Cormier JN; Pisters PW; Pollock RE; Feig BW
Am J Surg; 2003 Dec; 186(6):665-9. PubMed ID: 14672776
[TBL] [Abstract][Full Text] [Related]
17. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.
Le Cesne A; Ray-Coquard I; Bui BN; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Cioffi A; Emile JF; Chabaud S; Pérol D; Blay JY;
Lancet Oncol; 2010 Oct; 11(10):942-9. PubMed ID: 20864406
[TBL] [Abstract][Full Text] [Related]
18. Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec).
Joensuu H
Med Klin (Munich); 2002 Jan; 97 Suppl 1():28-30. PubMed ID: 11831069
[TBL] [Abstract][Full Text] [Related]
19. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
[TBL] [Abstract][Full Text] [Related]
20. [Imatinib--a breakthrough in the treatment of gastrointestinal stromal tumors (GIST)].
Larsen JB
Ugeskr Laeger; 2003 Sep; 165(37):3503-7. PubMed ID: 14531349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
